Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Conditions

Rare Diseases 1Neurologic Manifestations 1Mental Disorders 1Lambert-Eaton Myasthenic Syndrome 1

Interventions

Standard of Care 2Selective Serotonin Reuptake Inhibitors 1Methylphenidate 1Memory and Learning Tests 1Interviews as Topic 1Immunoglobulins 1Forest Therapy 1Dialectical Behavior Therapy 1Cognitive Behavioral Therapy 1Citalopram 1Behavior Therapy 1Amifampridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Mental Disorders × Amifampridine × Clear all
NCT00004832 2015-03-25

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

FDA Office of Orphan Products Development

Phase NA Completed
26 enrolled

Mental Disorders, Neurologic Manifestations, Lambert-Eaton Myasthenic Syndrome, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡